EMEA-000901-PIP04-17-M01

Key facts

Invented name
Jakavi
Active substance
Ruxolitinib (phosphate)
Therapeutic area
Oncology
Decision number
P/0384/2019
PIP number
EMEA-000901-PIP04-17-M01
Pharmaceutical form(s)
  • Tablet
  • Age-appropriate dosage form
Condition(s) / indication(s)
Treatment of chronic Graft versus Host Disease (cGvHD)
Route(s) of administration
  • Oral use
  • Gastric use
Contact for public enquiries
Novartis Europharm Limited

Tel. +41 6132 41111
E-mail: paediatric.enquiries@novartis.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating